Deintensifying diabetes treatment does not increase the risk for short-term adverse outcomes in male nursing home residents with limited life expectancy or advanced dementia, say researchers.
A post-hoc analysis of the DAPA-HF trial indicates that dapagliflozin is beneficial in people with heart failure and reduced ejection fraction regardless of frailty, but with the largest gains in the frailest individuals.
Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.
Less than a third of nursing home residents who meet the criteria for overtreatment of type 2 diabetes have their treatment deintensified, suggests an analysis of Veterans Affairs data.
Older adults with type 1 diabetes spend more time in target glucose range when using the Cambridge hybrid closed-loop insulin delivery system than when using sensor-augmented pump delivery, shows a randomized trial.
Older adults with a longer duration of type 1 diabetes have an increased likelihood of experiencing depression and hypoglycemia unawareness, researchers report.
Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.
Intensification of diabetes medications in older adults at the point of discharge from hospital is associated with an increased risk for hypoglycemia, without gains in glycemic control, research suggests.